Volume 80, Issue 9, Pages (November 2011)

Slides:



Advertisements
Similar presentations
Beta blockers in the management of chronic kidney disease
Advertisements

Volume 88, Issue 5, Pages (November 2015)
Volume 84, Issue 2, Pages (August 2013)
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction 
Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole
Viper venom for diabetic nephropathy
Anemia management in chronic kidney disease
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.
C-reactive protein and dialysis access
Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani 
Membranous nephropathy: When and how to treat
Viper venom for diabetic nephropathy
C-reactive protein and dialysis access
Volume 75, Issue 11, Pages (June 2009)
John P. Middleton, Patrick H. Pun  Kidney International 
Propofol as a panacea for acute kidney injury?
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Jeffrey C. Fink, Glenn M. Chertow  Kidney International 
Volume 94, Issue 3, Pages (September 2018)
Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?  Fu L. Luan, Diane E. Steffick,
Steven J. Rosansky, Richard J. Glassock  Kidney International 
The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis  Sai Subhodhini Reddy, Jean L. Holley 
Volume 82, Issue 3, Pages (August 2012)
Volume 72, Issue 12, Pages (December 2007)
Nephrology Crosswords: Hemodialysis
Fernando Elijovich, Cheryl L. Laffer  Kidney International 
Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension  A. Davenport, C. Cox, R. Thuraisingham  Kidney.
The analysis of survival data: the Kaplan–Meier method
Prescribing and monitoring hemodialysis dose
Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect?  Areef Ishani, Charles A. Herzog,
Volume 73, Issue 12, Pages (June 2008)
Volume 75, Issue 11, Pages (June 2009)
David M. Charytan, John P. Forman  Kidney International 
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
The future of renoprotection: Frustration and promises
Alternate-day dialysis may be needed for hemodialysis patients
Volume 84, Issue 5, Pages (November 2013)
Hepatitis C treatment in patients with kidney disease
Nephrology Crossword: Glomerulonephritis
Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter?  Dimitris Mavridis, PhD  American Journal.
A man with a hole in his penis
Volume 82, Issue 9, Pages (November 2012)
Volume 81, Issue 7, Pages (April 2012)
Carmine Zoccali, Francesca Mallamaci  Kidney International 
Volume 73, Issue 5, Pages (March 2008)
Organ transplantation goes to the movies
Volume 68, Issue 5, Pages (November 2005)
Volume 80, Issue 10, Pages (November 2011)
Renin–angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center  Oliver Lenz, Alessia Fornoni  Kidney International 
Volume 80, Issue 10, Pages (November 2011)
Volume 64, Issue 4, Pages (October 2003)
Charles A. Herzog  Kidney International 
Juan Jesús Carrero, PhD  American Journal of Kidney Diseases 
Importance of blood pressure control in hemodialysis patient survival
Volume 74, Issue 9, Pages (November 2008)
Volume 75, Issue 7, Pages (April 2009)
Volume 82, Issue 9, Pages (November 2012)
Potential Impact of Nutritional Intervention on End-Stage Renal Disease Hospitalization, Death, and Treatment Costs  Eduardo Lacson, MD, T. Alp Ikizler,
Antioxidant therapy in hemodialysis patients: a systematic review
(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.
Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga 
Volume 87, Issue 6, Pages (June 2015)
Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system  Victoria A. Kumar, Margo A. Sidell,
E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins 
Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Proteinuria and hypertension with tyrosine kinase inhibitors
Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy  Andrea M. Steely, MD, Peter W.
Presentation transcript:

Volume 80, Issue 9, Pages 978-985 (November 2011) Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients  Kevin E. Chan, T. Alp Ikizler, Jorge L. Gamboa, Chang Yu, Raymond M. Hakim, Nancy J. Brown  Kidney International  Volume 80, Issue 9, Pages 978-985 (November 2011) DOI: 10.1038/ki.2011.228 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Cardiovascular survival curves. (a) Crude and (b) adjusted survival curves in patients in whom angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy was initiated. Kidney International 2011 80, 978-985DOI: (10.1038/ki.2011.228) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Cardiovascular survival curves. (a) Crude and (b) adjusted survival curves in patients in whom treatment was initiated with an ACEI+other antihypertensive (antiHTN) medications (ACEI+Rx), an angiotensin receptor blocker (ARB)+antiHTN (ARB+Rx), or an ACEI+ARB. ACEI, angiotensin-converting enzyme inhibitor. Kidney International 2011 80, 978-985DOI: (10.1038/ki.2011.228) Copyright © 2011 International Society of Nephrology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.